Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egor Veselovsky

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Molecular Medicine|May 1, 2022
Transcriptomic Signatures in Colorectal Cancer ProgressionPavel Ershov, Stanislav Poyarkov, Yulia Konstantinova, et al.
JCO Precision Oncology|June 14, 2023
Microsatellite Instability Detection: The Current Standards, Limitations, and MisinterpretationsValentina Yakushina, Alexandra Kavun, Egor Veselovsky, et al.
Cancers|May 16, 2023
Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor TherapyAlexandra Kavun, Egor Veselovsky, Alexandra Lebedeva, et al.
Frontiers in Immunology|February 20, 2025
Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive diseaseDaria Kravchuk, Alexandra Lebedeva, Olesya Kuznetsova, et al.
Heliyon|May 6, 2024
Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experienceAlexandra Lebedeva, Olesya Kuznetsova, Maxim Ivanov, et al.
Scientific Reports|October 8, 2024
Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatmentEgor Veselovsky, Alexandra Lebedeva, Olesya Kuznetsova, et al.
International Journal of Molecular Sciences|April 17, 2025
The Role of MSI Testing Methodology and Its Heterogeneity in Predicting Colorectal Cancer Immunotherapy ResponseAlexandra Lebedeva, Anastasiia Taraskina, Tatiana Grigoreva, et al.
Molecular Diagnosis & Therapy|October 5, 2024
Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of DiscordanceAlexandra Lebedeva, Ekaterina Belova, Alexandra Kavun, et al.
World Journal of Oncology|July 12, 2024
Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation TestingAlexandra Lebedeva, Egor Veselovsky, Alexandra Kavun, et al.
Journal of Clinical Laboratory Analysis|March 8, 2025
Analytical and Clinical Validation of Solo-Test Driver: A Targeted Amplicon-Based NGS Test-System for FFPE and cfDNA Analysis in Clinical Oncology SettingMaxim Ivanov, Alexandra Lebedeva, Ekaterina Belova, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Molecular Medicine|May 1, 2022
Transcriptomic Signatures in Colorectal Cancer ProgressionPavel Ershov, Stanislav Poyarkov, Yulia Konstantinova, et al.
JCO Precision Oncology|June 14, 2023
Microsatellite Instability Detection: The Current Standards, Limitations, and MisinterpretationsValentina Yakushina, Alexandra Kavun, Egor Veselovsky, et al.
Cancers|May 16, 2023
Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor TherapyAlexandra Kavun, Egor Veselovsky, Alexandra Lebedeva, et al.
Frontiers in Immunology|February 20, 2025
Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive diseaseDaria Kravchuk, Alexandra Lebedeva, Olesya Kuznetsova, et al.
Heliyon|May 6, 2024
Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experienceAlexandra Lebedeva, Olesya Kuznetsova, Maxim Ivanov, et al.
Scientific Reports|October 8, 2024
Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatmentEgor Veselovsky, Alexandra Lebedeva, Olesya Kuznetsova, et al.
International Journal of Molecular Sciences|April 17, 2025
The Role of MSI Testing Methodology and Its Heterogeneity in Predicting Colorectal Cancer Immunotherapy ResponseAlexandra Lebedeva, Anastasiia Taraskina, Tatiana Grigoreva, et al.
Molecular Diagnosis & Therapy|October 5, 2024
Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of DiscordanceAlexandra Lebedeva, Ekaterina Belova, Alexandra Kavun, et al.
World Journal of Oncology|July 12, 2024
Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation TestingAlexandra Lebedeva, Egor Veselovsky, Alexandra Kavun, et al.
Journal of Clinical Laboratory Analysis|March 8, 2025
Analytical and Clinical Validation of Solo-Test Driver: A Targeted Amplicon-Based NGS Test-System for FFPE and cfDNA Analysis in Clinical Oncology SettingMaxim Ivanov, Alexandra Lebedeva, Ekaterina Belova, et al.
Pageof 2